Hemoglobin-vesicles for a transfusion alternative and targeted oxygen delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Biochemistry

Background:

• Hemoglobin-vesicles (HbV) are artificial oxygen carriers.
• HbV encapsulate purified hemoglobin solution within unilamellar phospholipid vesicles (liposomes).
• Surface modification with polyethylene glycol (PEG) ensures dispersion stability and room-temperature storage.

Purpose of the Study:

• To evaluate the safety and efficacy of HbV as a blood transfusion alternative.
• To demonstrate the tunable oxygen affinity (P50) of HbV for targeted oxygen delivery.
• To confirm the potential of HbV for oxygen transport in ischemic tissues.

Main Methods:

• Encapsulation of purified hemoglobin solution (35 g/dl) into liposomes.
• Surface modification of vesicles with polyethylene glycol (PEG).
• Regulation of oxygen affinity by co-encapsulating allosteric effectors like pyridoxal 5'-phosphate.

Main Results:

• HbV demonstrated stability at room temperature for extended periods.
• Intravenous injection of HbV did not induce aggregation with blood components.
• Animal experiments confirmed the safety and efficacy of HbV.
• Tunable P50 values achieved, mimicking red blood cell (RBC) oxygen affinity.
• Small HbV (250-280 nm) showed homogeneous distribution in plasma and potential for collateral transport in ischemic tissues.
• In vitro and in vivo studies confirmed targeted oxygen delivery capability.

Conclusions:

• HbV represent a promising, safe, and effective alternative to blood transfusions.
• The tunable oxygen affinity of HbV allows for targeted oxygen delivery to hypoxic tissues.
• HbV demonstrate potential for oxygen transport in ischemic conditions via collateral circulation.